Beyond Biotech - the podcast from Labiotech
Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane.
Beyond Biotech - the podcast from Labiotech
HaemaLogiX - precision immunotherapy for multiple myeloma
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
Today, we welcome Dr Rosanne Dunn, Chief Scientific Officer and co-founder of HaemaLogiX, an Australian clinical-stage biotech company that's developing next-generation immunotherapies for multiple myeloma and other plasma cell disorders.
HaemaLogiX is taking a precision approach by targeting novel antigens that are expressed exclusively on malignant plasma cells, sparing healthy ones. Recent peer-reviewed research has validated KMA and LMA as high-value targets, reinforcing the company's unique positioning in the field.
Rosanne shares her journey from antibody engineering to building HaemaLogiX, the science behind their differentiated targets, the latest clinical and preclinical progress, and her perspectives on the future of immunotherapy for blood cancers as the company gears up for key milestones, including a planned IPO later this year.
- 01:15 Meet Rosanne Dunn
- 07:52 HaemalogiX's mission and novel antigens
- 09:53 Overview of multiple myeloma and its symptoms
- 12:19 Targeting malignant plasma cells while sparing normal ones
- 19:25 Recent Peer-Reviewed Research
- 26:08 Synergy with IMiDs like Revlimid
- 29:08 Potential patient impact and quality of life
- 35:05 Planned IPO in 2026 and funding needs
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
To dive deeper into the topic: